Oncology Biosimilars Global Market Report 2024

Global Oncology Biosimilars Market Report 2024

Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

Name: Oncology Biosimilars Global Market Report 2024
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Oncology Biosimilars Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 250 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Oncology Biosimilars Global Market Report 2024

Proud Members Of

Oncology Biosimilars Market Definition

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy.

The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

Oncology Biosimilars Market Segmentation

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Global Oncology Biosimilars Market Size 2023 to 2028: Graph

Oncology Biosimilars Market Size 2024 And Growth Rate

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2023 to $8.85 billion in 2024 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars.

Oncology Biosimilars Market Growth Forecast

The oncology biosimilars market size is expected to see exponentially grown in the next few years. It will grow to $16.48 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

Book your 30 minutes free consultation with our research experts

Oncology Biosimilars Market Driver: Patent Expirations Drive New Oncology Biosimilars

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.

Oncology Biosimilars Market Driver: Government-Led Cancer Reduction Initiatives Catalysts For Oncology Biosimilars Market Growth

Government initiatives for reducing cancer are expected to propel the growth of the oncology biosimilars market going forward. Government initiatives refer to actions, policies, or programs introduced and implemented by government authorities at various levels (local, regional, national, or even international) to address specific issues or achieve particular objectives. These initiatives to reduce cancer can create a favorable environment for the development and adoption of oncology biosimilars by providing financial support, regulatory assistance, and public awareness. For instance, in 2022, according to National Cancer Institute, a US-based government agency, President Biden announced a reignition of the Cancer Moonshot, highlighting new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The Cancer Moonshot is marshaling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention. Therefore, government initiatives for reducing cancer drive the oncology biosimilars market.

Global Oncology Biosimilars Market Major Players

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Baxter International Inc., Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Shanghai Henlius Biotech, Viatris Inc., Catalent Inc., Patheon, Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Global Oncology Biosimilars Market Restraint: Unlocking The Potential Addressing The Awareness Gap Among Healthcare Professionals For Oncology Biosimilars

The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.

Global Oncology Biosimilars Market Trend: Fostering Innovation Through Research And Development For Oncology Biosimilars

The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business.

Global Oncology Biosimilars Market Trend: Increasing Focus On Investments To Support The Battle Of Cancer

Major companies operating in oncology biosimilars are investing in cancer drugs to support the battle of cancer. Company investments in oncology biosimilars emerge as a pivotal bridge between quality cancer care and sustainable healthcare solutions. For instance, in March 2023, Pfizer, a US-based pharmaceutical company merged with Seagen and invested $43 billion to battle cancer. This enhances Pfizer’s presence in the field of oncology and battle against cancer, a leading cause of death worldwide.

Regional Outlook For The Global Oncology Biosimilars Market

North America was the largest region in the global oncology biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Oncology Biosimilars Market Report Forecast And Analysis

Report Attribute	Details
Market Size Value In 2024	$8.85 billion
Revenue Forecast In 2033	$16.48 billion
Growth Rate	CAGR of 16.8% from 2024 to 2033
Base Year For Estimation	2023
Actual Estimates/Historical Data	2018-2023
Forecast Period	2024 - 2028 - 2033
Market Representation	Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered	1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regional Scope	Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Biocon Biologics Limited; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Pfizer Inc.; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; BIOCAD; Amgen Inc.; F. Hoffmann-La Roche; Baxter International Inc.; Sanofi SA; Mylan; Samsung Bioepis; Biogen International GmbH; Merck & Co. Inc.; Coherus Biosciences; Eli Lilly and Company; Novartis AG; Shanghai Henlius Biotech; Viatris Inc.; Catalent Inc.; Patheon; Accord Healthcare Ltd.; Zydus Cadila Health Care Limited; Hetero Drugs Limited; Mundipharma International Limited; Mabion SA; Polpharma Biologics; Alvotech; Innovent Biologics; Gan & Lee Pharmaceuticals; Henlius Biotech
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market

4.2. Ukraine-Russia War Impact On the Market

4.3. COVID-19 Impact On the Market

5. Global Oncology Biosimilars Market Size and Growth

5.1. Global Oncology Biosimilars Market Drivers and Restraints

5.1.1. Drivers Of The Market

5.1.2. Restraints Of The Market

5.2. Global Oncology Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

5.3. Global Oncology Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oncology Biosimilars Market Segmentation

6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Monoclonal Antibody

Immunomodulators

Hematopoietic Agents

Granulocyte Colony-Stimulating Factor (G-CSF)

6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Breast Cancer

Colorectal Cancer

Blood Cancer

Neutropenia Cancer

Non-Small Cell Lung Cancer

Other Cancer Types

6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

7. Oncology Biosimilars Market Regional And Country Analysis

7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

8.1. Asia-Pacific Oncology Biosimilars Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oncology Biosimilars Market

9.1. China Oncology Biosimilars Market Overview

9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oncology Biosimilars Market

10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oncology Biosimilars Market

11.1. Japan Oncology Biosimilars Market Overview

11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oncology Biosimilars Market

12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oncology Biosimilars Market

13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oncology Biosimilars Market

14.1. South Korea Oncology Biosimilars Market Overview

14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oncology Biosimilars Market

15.1. Western Europe Oncology Biosimilars Market Overview

15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oncology Biosimilars Market

16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oncology Biosimilars Market

17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oncology Biosimilars Market

18.5. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.6. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.7. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oncology Biosimilars Market

19.9. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.10. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.11. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oncology Biosimilars Market

20.13. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.14. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.15. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oncology Biosimilars Market

21.1. Eastern Europe Oncology Biosimilars Market Overview

21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oncology Biosimilars Market

22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oncology Biosimilars Market

23.1. North America Oncology Biosimilars Market Overview

23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oncology Biosimilars Market

24.1. USA Oncology Biosimilars Market Overview

24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oncology Biosimilars Market

25.1. Canada Oncology Biosimilars Market Overview

25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oncology Biosimilars Market

26.1. South America Oncology Biosimilars Market Overview

26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oncology Biosimilars Market

27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oncology Biosimilars Market

28.1. Middle East Oncology Biosimilars Market Overview

28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oncology Biosimilars Market

29.1. Africa Oncology Biosimilars Market Overview

29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

30.1. Oncology Biosimilars Market Competitive Landscape

30.2. Oncology Biosimilars Market Company Profiles

30.2.1. Biocon Biologics Limited

30.2.1.1. Overview

30.2.1.2. Products and Services

30.2.1.3. Strategy

30.2.1.4. Financial Performance

30.2.2. Celltrion Inc.

30.2.2.1. Overview

30.2.2.2. Products and Services

30.2.2.3. Strategy

30.2.2.4. Financial Performance

30.2.3. Dr. Reddy's Laboratories Ltd.

30.2.3.1. Overview

30.2.3.2. Products and Services

30.2.3.3. Strategy

30.2.3.4. Financial Performance

30.2.4. Intas Pharmaceuticals Ltd.

30.2.4.1. Overview

30.2.4.2. Products and Services

30.2.4.3. Strategy

30.2.4.4. Financial Performance

30.2.5. STADA Arzneimittel AG

30.2.5.1. Overview

30.2.5.2. Products and Services

30.2.5.3. Strategy

30.2.5.4. Financial Performance

31. Global Oncology Biosimilars Market Competitive Benchmarking

32. Global Oncology Biosimilars Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

34. Oncology Biosimilars Market Future Outlook and Potential Analysis

34.1 Oncology Biosimilars Market In 2028 - Countries Offering Most New Opportunities

34.2 Oncology Biosimilars Market In 2028 - Segments Offering Most New Opportunities

34.3 Oncology Biosimilars Market In 2028 - Growth Strategies

34.3.1 Market Trend Based Strategies

34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations

35.2. Currencies

35.3. Historic And Forecast Inflation Rates

35.4. Research Inquiries

35.5. The Business Research Company

35.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 9: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 10: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 11: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 12: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 13: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 14: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 15: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 16: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 17: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 18: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 19: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 20: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 21: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 22: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 23: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 24: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 25: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 26: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 27: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 28: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 29: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 30: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 31: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 32: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 33: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 34: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 35: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 36: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 37: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 38: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 39: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 40: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 41: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 42: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 43: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 44: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 45: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 46: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 47: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 48: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 49: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 50: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 51: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 52: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 53: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 54: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 55: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 56: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 57: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 58: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 59: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 60: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 61: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 62: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 63: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 64: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 65: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 66: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 67: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 68: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 69: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 70: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 71: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 72: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 73: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 74: Biocon Biologics Limited Financial Performance

Table 75: Celltrion Inc. Financial Performance

Table 76: Dr. Reddy's Laboratories Ltd. Financial Performance

Table 77: Intas Pharmaceuticals Ltd. Financial Performance

Table 78: STADA Arzneimittel AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2018-2023, $ Billion

Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 9: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 10: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 11: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 12: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 13: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 14: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 15: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 16: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 17: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 18: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 19: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 20: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 21: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 22: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 23: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 24: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 25: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 26: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 27: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 28: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 29: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 30: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 31: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 32: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 33: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 34: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 35: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 36: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 37: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 38: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 39: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 40: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 41: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 42: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 43: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 44: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 45: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 46: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 47: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 48: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 49: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 50: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 51: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 52: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 53: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 54: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 55: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 56: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 57: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 58: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 59: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 60: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 61: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 62: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 63: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 64: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 65: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 66: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 67: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 68: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 69: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 70: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 71: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 72: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 73: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 74: Biocon Biologics Limited Financial Performance

Figure 75: Celltrion Inc. Financial Performance

Figure 76: Dr. Reddy's Laboratories Ltd. Financial Performance

Figure 77: Intas Pharmaceuticals Ltd. Financial Performance

Figure 78: STADA Arzneimittel AG Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

Biosimilar Growth Hormones Global Market Report 2024 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Monoclonal Antibodies Global Market Report 2024 – By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application (Chronic & Autoimmune Diseases, Oncology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Therapeutic Peptides Global Market Report 2024 – By Type (Innovative, Generic), By Route Of Administration (Parenteral Route, Transdermal Route, Other Route Of Administrations), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Hormones Global Market Report 2024 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Interleukins Global Market Report 2024 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Lymphocyte Modulator Global Market Report 2024 – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Biosimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Biosimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Other Diseases, Distribution Channel (Online Pharmacies, direct to consumer) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Pharmaceuticals Global Market Report 2022 – By Type (Pharmaceutical Drugs, Biologics), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce), By Nature (Organic, Conventional) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Frequently Asked Questions

What is the definition of the oncology biosimilars market?

How will the oncology biosimilars market drivers and restraints affect the oncology biosimilars market dynamics? What forces will shape the oncology biosimilars industry going forward?

The oncology biosimilars market major growth driver - patent expirations drive new oncology biosimilars. For further insights on the oncology biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the oncology biosimilars market?

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2023 to $8.85 billion in 2024 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars. The oncology biosimilars market size is expected to see exponentially grown in the next few years. It will grow to $16.48 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence. For further insights on the oncology biosimilars market, request a sample here

How is the oncology biosimilars market segmented?

The oncology biosimilars market is segmented
1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy For further insights on the oncology biosimilars market, request a sample here

Which region has the largest share of the oncology biosimilars market? What are the other regions covered in the report?

North America was the largest region in the global oncology biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. For further insights on the oncology biosimilars market, request a sample here.

Who are the major players in the oncology biosimilars market?

What are the key trends in the oncology biosimilars market?

Major trend in the oncology biosimilars market - fostering innovation through research and development for oncology biosimilars. For further insights on the oncology biosimilars market, request a sample here.

What are the major opportunities in the oncology biosimilars market? What are the strategies for the oncology biosimilars market?

For detailed insights on the major opportunities and strategies in the oncology biosimilars market, request a sample here.

How does the oncology biosimilars market relate to the overall economy and other similar markets?

For detailed insights on oncology biosimilars market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the oncology biosimilars industry?

For detailed insights on the mergers and acquisitions in the oncology biosimilars industry, request a sample here.

What are the key dynamics influencing the oncology biosimilars market growth? SWOT analysis of the oncology biosimilars market.

For detailed insights on the key dynamics influencing the oncology biosimilars market growth and SWOT analysis of the oncology biosimilars industry, request a sample here.